Our pipeline includes drugs for chronic and acute pain, along with a safer version of aspirin.
Our lead drug, ATB-346, targets chronic pain and inflammation arising from a wide range of medical conditions. ATB-352 addresses the urgent need for a safer, non-addictive analgesic for treating post-operative pain, where many opioid addictions begin. ATB-340 is a gastrointestinal-safe derivative of aspirin.
Click on drug candidates below to learn more.
Keep up-to-date—check out the Investor Dashboard for share information, our Investor Presentation, financial statements, regulatory filings, latest news and more—everything you need in one place.
Understand the science behind our drug platform. Learn how Antibe’s drugs surpass current solutions. Investigate a diagram detailing hydrogen sulfide’s multiple roles in human biology.
Subscribe To Our Mailing List
Please sign up to our mailing list to receive regular news updates via e-mail.